Susquehanna International Group
PSTX

Susquehanna International Group’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Susquehanna International Group’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-246,800
Closed -$2.37M – 13803
2024
Q4 		$2.37M Buy
+246,800
New +$1.29M ﹤0.01% 4923
2024
Q3 		– Sell
-31,600
Closed -$92.3K – 13288
2024
Q2 		$92.3K Sell
31,600
-24,800
-44% -$67.8K ﹤0.01% 11077
2024
Q1 		$180K Buy
56,400
+14,900
+36% +$49.7K ﹤0.01% 10715
2023
Q4 		$139K Buy
+41,500
New +$107K ﹤0.01% 11037
2022
Q4 		– Sell
-14,900
Closed -$53K – 13958
2022
Q3 		$53K Buy
+14,900
New +$49.3K ﹤0.01% 12168
2021
Q4 		– Sell
-18,000
Closed -$131K – 14082
2021
Q3 		$131K Buy
+18,000
New +$154K ﹤0.01% 11889

Other funds holding PSTX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Susquehanna International Group's PSTX Position: Q1 2025 in Review

Susquehanna International Group sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 198,375 shares — an estimated $1.9M sold.

Susquehanna International Group first reported a position in PSTX in Q1 2021 and held it in 11 quarters. The position peaked at $2.01M in Q1 2023. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.

  • Susquehanna International Group reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Susquehanna International Group sold 198,375 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $1.9M.
  • Susquehanna International Group first reported a position in Poseida Therapeutics, Inc. Common Stock in Q1 2021 and held it in 11 quarters.
  • Susquehanna International Group's Poseida Therapeutics, Inc. Common Stock position peaked at $2.01M in Q1 2023.
  • 1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Susquehanna International Group's 13F filing for Q1 2025, filed 14 May 2025.